Cover Image
市場調查報告書

全球抗病毒藥物市場預測:市場規模、區分、市場佔有率、競爭情形

Global Antiviral Drugs Market Segmented by Therapeutics and Geography - Growth, Trends and Forecasts (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 367215
出版日期 內容資訊 英文 193 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球抗病毒藥物市場預測:市場規模、區分、市場佔有率、競爭情形 Global Antiviral Drugs Market Segmented by Therapeutics and Geography - Growth, Trends and Forecasts (2017 - 2022)
出版日期: 2017年01月24日 內容資訊: 英文 193 Pages
簡介

本報告提供全球抗病毒藥物市場相關調查分析、市場概要、市場動態、各市場區隔分析、競爭情形等系統性資訊。

簡介

調查手法

摘要整理

主要的推論

市場概要與產業趨勢

  • 目前市場方案
  • 市場概要
  • 新的發展
  • 五力

推動因素、阻礙因素、機會、課題分析 (DROC)

  • 推動市場要素
  • 阻礙市場要素
  • 主要課題
  • 目前機會

全球抗病毒藥物市場:各標的疾病

  • HIV/AIDS
  • 肝炎
  • 皰疹
  • 流感

全球抗病毒藥物市場:抗病毒的各類型

  • IPR保護
  • 學名藥

全球抗病毒藥物市場:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 中東、非洲
  • 南美

競爭情形

  • M&A分析
  • 新產品銷售
  • 契約、聯盟、夥伴關係

主要供應商分析

  • Abbott
  • Bristol-Myers-Squibb
  • Gilead
  • GlaxoSmithKline
  • Johnson & Johnson
  • MedImmune/AstraZeneca
  • Merck & Co
  • Roche
  • Schering-Plough

投資機會預測

市場未來發展預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

In 2014, the global antiviral market was estimated to be worth USD 27.6 billion and is expected to reach revenues of approximately USD 36.44 billion by 2019 at a CAGR of 5.71% between 2014 and 2019. The antiviral drugs are medicines that cure or control virus infections. They specifically inhibit one or more steps of virus replication without causing unacceptable side effects.

The antiviral drugs are used in the treatment of patients suffering from HIV, herpes viruses, the hepatitis B and C viruses, and influenza A and B viruses.

The global antiviral market is showing a moderate growth in the pharmaceutical market and is expected to reach higher levels due to increase in the diseased population, increase in awareness level and launch of new drugs with better efficacy and fewer side effects.

Market is estimated to be dominated by generic drugs in HIV, accounting for approximately 46% of the total generic drugs in 2010. HIV generics are expected to create a boom in the market, due to patent expiry of already existing drugs in the market. As a series of patent expiries, it opens opportunities for ambitious companies to seize huge revenues. Other driving factors for the market are Government policies which include the need for prior authorization in order to dispense branded drugs that have generic alternatives, while further incentives are available from Pharmacy Benefit Managers (PBM) for dispensing generic drugs. Major constraint for the market is limited resource for the access of treatment.

The generic market is currently dominated by products such as zidovudine, didanosine, stavudine and lamivudine. Overall antiviral market is driven by Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for 61% of the market 2010. At the end of 2012, 9.7 million people in low- and middle-income countries were on antiretroviral treatment (ART). The number of people on ART increased by 1.6 million in 2012, the biggest increase in one year to date.4 out of 5 people newly put on treatment lives in sub-Saharan Africa. In 21 African countries with a high burden of HIV 2 out of 3 people in need are receiving treatment, and 2 out of 3 positive pregnant women are receiving ARV drugs to prevent HIV transmission to their infants.

Market is segmented by therapeutics and by geography. By therapeutics market is segmented into HIV/ AIDS therapeutic market, Hepatitis Therapeutics Market, Herpes Therapeutics Market, Influenza Therapeutics Market. By geography market is segmented into North America, Europe and Asia-Pacific. In countries with Major ART scale-up such as Brazil or China, the death rate among people living with HIV has decreased by 80%. In 2012, the number of people living with HIV in India were 210, 0000 and in United States of America the number was between 9, 20,000-18, 00,000.

The key challenges faced by the market are increasing usage of natural products and high cost of developing drugs. The opportunities available for this market are increasing need for broad spectrum drugs and access to antiviral drugs in the pharmerging markets. The major companies for the antiviral drugs market globally are Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, MedImmune/AstraZeneca, Schering-Plough, Johnson & Johnson, Merck & Co are the major players in the market.

Key Deliverables of the Study

Market analysis for the Global Antiviral Drugs Market, with region specific assessments and competition analysis on global and regional scales

Market definition along with the identification of key drivers and restraints

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale

Extensively researched competitive landscape section with profiles of major companies along with their market

Identification and analysis of the macro and micro factors that affect the global ophthalmic drugs and devices market on both global and regional scales

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped

Table of Contents

1. Introduction

  • 1.1 Study Deliverables
  • 1.2 Market Definition
  • 1.3 Sizing Units
  • 1.4 Base Currency
  • 1.5 Review and Forecast Period Years
  • 1.6 General Study Assumptions

2. Research Methodology

  • 2.1 Introduction
  • 2.2 Analysis Methodology
  • 2.3 Econometric Forecast Model
  • 2.4 Research Assumptions

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry Trends

  • 5.1 Current Market Scenario
  • 5.2 Therapeutic Segments for Antiviral Drugs
  • 5.3 New Drugs
  • 5.4 PorterFive Forces
    • 5.4.1 Bargaining Power of Suppliers
    • 5.4.2 Bargaining Power of Consumers
    • 5.4.3 Threat of New Entrants
    • 5.4.4 Threat of Substitute Products and Services
    • 5.4.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Increased Nanotechnology in Developing Antiviral Agents
    • 6.1.2 Technical breakthroughs in the development of antivirals
    • 6.1.3 Increasing Unmet Needs and Population Growth
  • 6.2 Market Restraints
    • 6.2.1 Lack of a widespread antiviral to treat multiple viral infections
    • 6.2.2 Increasing Market for Generics
    • 6.2.3 High Risk of Failure and Government Firmness
  • 6.3 Key Challenges
    • 6.3.1 Increasing usage of natural products for the development of Antiviral drug
    • 6.3.2 High cost of developing drugs
  • 6.4 Current Opportunities in the Market
    • 6.4.1 Increasing Need for Broad-Spectrum Drugs
    • 6.4.2 Access to Antiviral Drugs in Pharmerging Markets

7. Global Antivirals Drugs Market, by Technology, By Therapeutic Area

  • 7.1 HIV/AIDS Therapeutics Market
  • 7.2 Hepatitis Therapeutics Market
  • 7.3 Herpes Therapeutics Market
  • 7.4 Influenza Therapeutics Market

8. Global Antivirals Drugs Market, by Technology, By Type

  • 8.1 Branded
  • 8.2 Genetics

9. Global Antiviral Drugs Market, By Geography

  • 9.1 North America
    • 9.1.1 Introduction
    • 9.1.2 United States
    • 9.1.4 Mexico
    • 9.1.4 Canada
  • 9.2 Europe
    • 9.2.1 Introduction
    • 9.2.2 Germany
    • 9.2.3 France
    • 9.2.4 United Kingdon
    • 9.2.5 Italy
    • 9.2.6 Spain & Portugal
    • 9.2.7 Scandinavia
  • 9.3 Asia-Pacific (APAC)
    • 9.3.1 Introduction
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Australia & New Zealand
  • 9.4 Middle East & North Africa (MENA)
    • 9.4.1 Introduction
    • 9.4.2 Saudi Arabia
    • 9.4.3 United Arab Emirates
    • 9.4.4 Israel
    • 9.4.5 GCC
    • 9.4.6 Algeria
  • 9.5 South America
    • 9.5.1 Introduction
    • 9.5.2 Brazil
    • 9.5.3 Argentina
    • 9.5.4 Colombia
    • 9.5.5 Chile
    • 9.5.6 Venezuela

10. Competitive Landscape

  • 10.1 Merger and Acquisition Analysis
  • 10.2 Patent Analysis
  • 10.3 The Challengers

11. Key Vendor Analysis

  • 11.1 Abbott
  • 11.2 Bristol-Myers-Squibb
  • 11.3 Gilead
  • 11.4 GlaxoSmithKline
  • 11.5 Johnson & Johnson
  • 11.6 MedImmune/AstraZeneca
  • 11.7 Merck & Co
  • 11.8 Roche
  • 11.9 Schering-Plough

12. Analyst Outlook for Investment Opportunities

13. Future Outlook of the Market

Back to Top